布地奈德福莫特罗(Budesonide/Formoterol Fumarate Dihydrate) - 药物靶点：GR x β2-adrenergic receptor_在研适应症：轻度哮喘，哮喘，慢性阻塞性肺疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Budesonide and Formoterol Fumarate、Budesonide/Formoterol、Formoterol Fumarate Hydrate/Budesonide

+ [19]

靶点

GR x β2-adrenergic receptor

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Teva Pharmaceuticals Europe BVAstraZeneca LP

AstraZeneca PLC

+ [7]

非在研机构

Pearl Therapeutics, Inc.

最高研发阶段批准上市

首次获批日期

澳大利亚 (2002-05-27),

哮喘慢性阻塞性肺疾病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C92H124N4O26

InChIKeySTZCUPXZOQOJNR-BQOVXDGUSA-N

CAS号1089666-88-5

关联

223

项与布地奈德福莫特罗相关的临床试验

NCT06597682

/ Not yet recruitingN/AIIT

A Randomized Controlled Basket Study for Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction (RISE)

This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided into an experimental group and a control group, Patients who do not accept treatment can be included in the observational cohort. Subjects in the experimental group receive immunomodulatory interventions plus conventional treatment, while subjects in the control group receive conventional treatment only. Subjects in each symptom cluster undergo clinical medical record data collection, laboratory tests, and imaging examinations at specified time points, as well as records of adverse events.

开始日期2025-03-01

申办/合作机构

复旦大学附属华山医院

NCT06676319

/ Recruiting临床2期

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma.
The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments.
Study details include:
* The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study.
* The investigational treatment duration will be up to approximately 52 weeks.
* The number of visits will be 18.

开始日期2024-11-07

申办/合作机构

Sanofi

NCT06590740

/ RecruitingN/A

Establishment of a FeNO Cutoff Value for Evaluating the Response to Budesonide-formoterol in Patients With Chronic Cough Suggestive of Cough Variant Asthma: a Multicenter Prospective Clinical Study

This is a multicenter, prospective, single-arm, interventional clinical study to predict the response to budesonide-formoterol treatment in patients with chronic dry or nocturnal cough by determining a cut off value of FeNO. In this study, the response to ICS/LABA treatment is defined as reduction in cough VAS score from baseline of ≥30 mm after 8 weeks of ICS/LABA treatment. Subjects will be treated with Symbicort® 160/4.5 mcg, 1 puff, BID for 8 weeks with 4 study visits: Visit 1 (Day 0), Visit 2 (week 4) and Visit 3, end of study (week 8) and Visit 4, 4 weeks after treatment discontinuation, (week 12). Baseline data will be collected at Day-5 to Day0.
This study will be conducted at around 40 study sites in China. Approximately 1000 patients (age ≥18 years old) with dry cough or nocturnal cough symptoms for at least 8 weeks and no other obvious cause for their cough will be enrolled into this study.

开始日期2024-10-25

申办/合作机构

AstraZeneca PLC

100 项与布地奈德福莫特罗相关的临床结果

登录后查看更多信息

100 项与布地奈德福莫特罗相关的转化医学

登录后查看更多信息

100 项与布地奈德福莫特罗相关的专利（医药）

登录后查看更多信息

596

项与布地奈德福莫特罗相关的文献（医药）

2025-04-03·JOURNAL OF ASTHMA

Budesonide/formoterol turbuhaler vs pMDI salbutamol for acute asthma in outpatient emergency department: a prospective, randomized, open-label study

Article

作者: Mohd Pauzi, Zulsairi ; Chong, Woon Wee ; Lai, Sin Nan ; Koh, Hock Peng

BACKGROUND:

The Global Initiative for Asthma (GINA) has suggested the need for more studies on inhaled corticosteroid (ICS)-formoterol in the Emergency Department (ED).

OBJECTIVES:

We aimed to compare the outcomes of budesonide/formoterol (160/4.5 mcg/inhalation) turbuhaler versus pressurized metered-dose inhaler (pMDI) salbutamol (100 mcg/puff) in acute asthma in the outpatient ED.

METHODS:

This single-centre, prospective, randomized, and open-label study involved adult asthma patients with mild to moderate asthma exacerbation who attended the outpatient ED of a tertiary hospital in Malaysia. The intervention arm received budesonide/formoterol (Symbicort^® 160/4.5 mcg) turbuhaler, while the control arm received pMDI salbutamol with a valved holding chamber. Stratified randomization with variable baseline ICS use was employed. Direct discharge rate from outpatient ED was the primary outcome. Vital signs pre- and post-treatment between the two arms were also compared.

RESULTS:

Seventy-four (n = 37 for each arm) asthma patients were recruited. Baseline clinical characteristics were comparable between the two arms. Direct discharge rates from ED were comparable between the intervention (94.6%) and the control (91.9%) arms (p = 1.000). Post-treatment outcomes (respiratory rate, oxygen saturation, peak expiratory flow rate) were similar between the two arms, except for the higher increment of heart rate (p < 0.001) and lesser reduction of blood pressure in the control arm (p = 0.013). Intravenous hydrocortisone use was significantly higher in the control arm (n = 19, 51.4%) than in the budesonide/formoterol arm (n = 6, 16.2%) (p = 0.001).

CONCLUSION:

Budesonide/formoterol turbuhaler is as effective as pMDI salbutamol in treating asthma exacerbation in the outpatient ED with less effect on heart rate and lower usage of intravenous corticosteroids.

2025-02-01·AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS)

Article

作者: Arya, Niki ; Fredriksson, Martin ; Parikh, Himanshu ; Bowen, Karin ; Singh, Dave ; Movitz, Charlotta ; Mushunje, Alec ; Hurst, John R. ; Ojili, Nikki ; Patel, Mehul ; Kisielewicz, Dobrawa ; Han, MeiLan K. ; Martinez, Fernando J. ; Gale, Chris P.

Rationale: Chronic obstructive pulmonary disease (COPD) is associated with an increased risk of cardiovascular and cardiopulmonary events. In the phase III, 52-week ETHOS trial (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF) reduced rates of moderate/severe exacerbations and all-cause mortality compared with dual therapy with glycopyrrolate/formoterol fumarate (GFF) or budesonide/formoterol fumarate (BFF). However, the effect of BGF on cardiovascular events versus GFF remains unevaluated. Furthermore, the effect of BGF on time to first severe exacerbation has not been reported. Objectives: To assess the effects of BGF 320/18/9.6 μg (BGF 320) and other inhaled corticosteroid-containing arms on cardiovascular and severe cardiopulmonary endpoints versus GFF in patients with COPD from the ETHOS trial. Methods: Patients with moderate to very severe COPD and a history of exacerbations were randomized to twice-daily BGF 320, BGF 160/18/9.6 μg, BFF 320/9.6 μg, or GFF 18/9.6 μg (GFF). Time to first severe COPD exacerbation was a prespecified endpoint; post hoc cardiovascular and severe cardiopulmonary endpoints included time to first major adverse cardiac event, time to first cardiovascular adverse event (AE) of special interest, time to first cardiac AE, and time to the composite endpoint of first severe cardiopulmonary event. Measurements and Main Results: BGF 320 reduced the rate of first occurrence (hazard ratio [95% confidence interval]) of cardiovascular and severe cardiopulmonary events versus GFF, including for time to first cardiovascular adverse event of special interest (0.63 [0.48, 0.82]), cardiac AE (0.60 [0.48, 0.76]), and severe cardiopulmonary event (0.80 [0.67, 0.95]). Conclusions: BGF had a benefit on cardiovascular endpoints and severe cardiopulmonary events versus GFF in patients with moderate to very severe COPD.

2025-01-01·Food science and technology international = Ciencia y tecnologia de los alimentos internacional

Effect of fat replacement by flaxseed flour on the quality parameters of pork meatballs

Article

作者: Fan, Wenjiao ; Xu, Chengjian ; Qiao, Mingfeng ; Wu, Huachang ; Deng, Jing ; Dong, Ping ; Zhu, Kaixian ; Xiao, Lan ; Yang, Huizhen

To improve the edible qualities of meatballs, various percentages of pork fat in meatballs were replaced by brown flaxseed flour (BFF) to decrease the fat contents and further optimize the fatty acid compositions. Five different meatball formulations that used 0%, 5%, 10%, 15%, and 20% of flaxseed flour additions were used in which the corresponding amounts pork fat were replaced. The proximate compositions, water activity, pH levels, colors, textures, cooking losses, fatty acid compositions, sensory properties, flavors, and oxidation stabilities of these meatballs were analyzed. Increasing the BFF addition amounts improved the protein and dietary fiber contents, pH levels, fatty acid profiles and oxidation stabilities, but decreased the fat contents, moisture levels, cooking losses, n6/n3 ratios, hardness, and lightness. The volatile flavors of meatballs with different BFF replacement levels were significantly different. According to the sensory evaluation, the use of 5% BFF increased the odor of meatballs without significantly affecting the other sensory scores. This work demonstrated that BFF may be a healthier alternative as pork fat replacer for preparing meatballs.

153

项与布地奈德福莫特罗相关的新闻（医药）

2025-03-17

·PRNewswire

Chance Pharma Secures New Funding to Accelerate Development of Innovative Inhalation Therapies

HANGZHOU, China, March 17, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced the successful completion of a new round of financing. Heda Health Fund and Qihang Venture Capital participated in this round. The proceeds will support the advancement of Phase III clinical trials for CXG87, an improved formulation of budesonide/formoterol inhalation powder, as well as the development of several innovative inhalation powder formulations. Lighthouse Capital acted as the exclusive financial advisor for this transaction. Dr. Donghao Chen, Founder and CEO of Chance Pharma, commented, "We are deeply grateful to our investors for their trust and support. This financing marks a pivotal milestone for Chance Pharma as we enter a critical phase. The funding will significantly accelerate the Phase III clinical trials of CXG87, a product with great clinical and commercial potential. Furthermore, it will strengthen our innovative inhaled drug development capabilities, anchored by our proprietary spray-dried formulation platform. Moving forward, we will continue to leverage our unique technological expertise to address unmet clinical needs, foster collaborations with domestic and international partners, and deliver safe, efficacious, and cost-effective treatment options to patients worldwide." About Chance Pharmaceuticals Chance Pharmaceuticals is a clinical-stage biotechnology company dedicated to the research and development of innovative dry powder inhalation (DPI) therapies. The company's pipeline is supported by two core technology platforms: milling and mixing, and spray drying. Its proprietary spray drying platform enables the transformation of biological macromolecules, low-activity drugs, and deep lung/systemic delivery drugs into highly efficient dry powder inhalation formulations. Chance Pharma operates state-of-the-art production facilities compliant with FDA and EMA quality standards, underscoring its strong capabilities in both R&D and manufacturing. Through independent innovation and strategic partnerships, the company is advancing a diverse portfolio of programs targeting respiratory diseases, central nervous system (CNS) disorders, and fibrotic diseases. For more information, please visit . Contact Information: Hangzhou Chance Pharma Guobao Zhao [email protected] +86 571-8630-9565 Goby Global Bob Ai [email protected] +1 646-389-6658 SOURCE Chance Pharmaceuticals WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期

2025-03-11

·米内网

【瞩目】四川药企拿下17亿高端吸入剂

精彩内容近日，国家药监局官网显示，四川普锐特药业（倍特药业子公司）申报的4类仿制药沙美特罗替卡松吸入粉雾剂获批生产并视同过评，为国产第2家获批，原研产品2023年在中国三大终端六大市场（统计范围详见本文末）的销售额超过17亿元。沙美特罗替卡松吸入粉雾剂是由沙美特罗（长效β2受体激动剂）和丙酸氟替卡松（吸入性糖皮质激素）组成的复方制剂，适用于可逆性气道阻塞性气道疾病的规律治疗，包括成人和儿童哮喘等。米内网数据显示，沙美特罗替卡松吸入粉雾剂已被纳入国家医保乙类目录，2023年在中国三大终端六大市场的销售额超过17亿元，2024上半年超过9亿元，在化药吸入剂品牌排名中，葛兰素史克的沙美特罗替卡松吸入粉雾剂排位第三。近年来中国三大终端六大市场沙美特罗替卡松吸入粉雾剂销售情况（单位：万元）来源：米内网格局数据库目前国内有10余家企业布局沙美特罗替卡松吸入粉雾剂仿制药，其中健康元药业的产品经过多次申报，最终于2024年6月获批生产，拿下国内首仿+首家过评；杭州京瑞医药、四川普锐特药业的产品紧接在后，陆续获批。此外，欧米尼、西普拉、润生药业、Celon等企业的产品报产在审。作为药械合一的特殊制剂产品，吸入剂的研发门槛较高。目前倍特药业已拥有11款吸入剂的生产批文，包括吸入用布地奈德混悬液、吸入用硫酸沙丁胺醇溶液、吸入用异丙托溴铵溶液、盐酸左沙丁胺醇雾化吸入溶液等畅销品种。此外，8个吸入剂以新注册分类申报在审，咪达唑仑鼻喷雾剂、布地奈德福莫特罗吸入气雾剂、糠酸莫米松富马酸福莫特罗吸入气雾剂、丙酸氟替卡松吸入气雾剂等在国内均暂无仿制药获批。倍特药业以新注册分类申报的吸入剂来源：米内网中国申报进度（MED）数据库吸入剂新药方面，3月7日，四川普锐特药业的1类新药PRT-064040鼻喷雾剂提交IND获受理。此前，公司已有3款吸入剂新药处于获批临床及以上阶段，其中1类新药吸入用XQ-001、2类改良型新药盐酸右氯胺酮鼻喷雾剂已步入I期临床。资料来源：米内网数据库、国家药监局官网等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至3月11日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

临床申请上市批准

2025-03-04

·美迪西Medicilon

北恒生物CAR-T细胞疗法IND申请获FDA批准 | 1分钟药闻速览

医线药闻 3月1日，北恒生物宣布其靶向CD7的通用型CAR-T细胞疗法CTD402已获得美国食品药品监督管理局（FDA）的新药临床试验申请（IND）批准，用于治疗复发/难治性T细胞急性淋巴细胞白血病/淋巴瘤（R/R T-ALL/LBL）的儿童及成人患者。 3月4日，CDE官网公示，信达生物1类新药IBI3007获批临床，拟开发治疗晚期恶性实体瘤。这是一款靶向TROP2的免疫刺激抗体偶联物（ISAC），本次是该产品首次在中国获批IND。 3月4日，CDE官网公示，默沙东（MSD）申报的来特莫韦微片拟纳入优先审评，用于接受异基因造血干细胞移植（HSCT）的巨细胞病毒（CMV）血清学阳性的成人和6个月及以上且体重≥6kg的儿童受者[R+]预防巨细胞病毒感染和巨细胞病毒病。来特莫韦是一种新型非核苷类巨细胞病毒（CMV）抑制剂。 3月4日，罗氏（Roche）旗下基因泰克（Genentech）宣布，美国FDA已批准血栓溶解剂TNKase（tenecteplase）上市，用于治疗成人急性缺血性中风（AIS）。新闻稿指出，TNKase是FDA近30年来批准的首款中风药物。投融药事 3月4日，杭州畅溪制药有限公司宣布完成新一轮融资，本轮融资由浙江省“4+1”生物医药与高端器械产业基金，启航投资共同参与投资。本轮融资将用于推进CXG87（改良型布地奈德/福莫特罗吸入粉雾剂）三期临床试验，以及多个创新型吸入粉雾剂的开发。科技药研 3月3日，国际顶尖学术期刊 Nature 以加速上线形式发表了来自四川大学华西医院邓成教授团队题为：Constitutively active glucagon receptor drives high blood glucose in birds 的研究论文。该研究表明，胰高血糖素受体（GCGR）的高表达和组成性活性的结合，驱动了鸟类的高血糖和体重降低，这可能促进了鸟类祖先的飞行进化。 [1]Zhang, C., Xiang, X., Liu, J. et al. Constitutively active glucagon receptor drives high blood glucose in birds. Nature (2025). https://doi-org.libproxy1.nus.edu.sg/10.1038/s41586-025-08811-8

细胞疗法临床3期临床申请优先审批免疫疗法

100 项与布地奈德福莫特罗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	布地奈德福莫特罗	R03AK07	-

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
轻度哮喘	英国	AstraZeneca PLC	2023-03-23
哮喘	澳大利亚	AstraZeneca Pty Ltd.	2002-05-27
慢性阻塞性肺疾病	澳大利亚	AstraZeneca Pty Ltd.	2002-05-27

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
儿童哮喘	临床3期	法国	AstraZeneca PLC	2021-08-23
纤毛运动障碍	临床3期	美国	AstraZeneca PLC	2007-01-01
纤毛运动障碍	临床3期	波多黎各	AstraZeneca PLC	2007-01-01
家族性嗜酸性粒细胞增多症	临床3期	丹麦	AstraZeneca PLC	2005-05-01
家族性嗜酸性粒细胞增多症	临床3期	法国	AstraZeneca PLC	2005-05-01
家族性嗜酸性粒细胞增多症	临床3期	德国	AstraZeneca PLC	2005-05-01
家族性嗜酸性粒细胞增多症	临床3期	西班牙	AstraZeneca PLC	2005-05-01
家族性嗜酸性粒细胞增多症	临床3期	瑞典	AstraZeneca PLC	2005-05-01
家族性嗜酸性粒细胞增多症	临床3期	英国	AstraZeneca PLC	2005-05-01
气道病变	临床3期	瑞典	AstraZeneca PLC	2004-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04159519 (CTgov)	临床4期	哮喘 \| 嗜酸性粒细胞性哮喘	170	salbutamol+Symbicort+benralizumab (Treatment Reduction)	窪膚遞鑰鬱構蓋醖鹽願 = 蓋獵憲壓蓋範築鑰鏇糧夢鏇獵憲製繭鹹鏇鏇淵 (鬱餘艱艱鑰夢憲壓遞憲, 淵積築積夢艱製餘夢憲 ~ 願餘窪網範獵構遞構積) 更多	-	2025-01-09
				salbutamol+Symbicort+benralizumab (Reference)	壓觸鬱積鑰觸淵衊襯夢(願獵鑰鏇鏇鹽鬱獵網築) = 襯夢蓋鏇糧遞選願夢構顧夢醖鬱範醖艱獵築鏇 (顧顧繭醖糧觸窪獵壓蓋, 0.0677) 更多
CTR20180475 (CTR20180475, Pubmed \| COPD)	临床3期	慢性阻塞性肺疾病	750	Beclometasone Dipropionate/Formoterol Fumarate	醖築範鏇鏇醖膚醖齋齋(蓋餘顧衊願齋淵獵醖窪) = 廠鹽淵顧衊願糧鑰範網廠淵壓遞鏇獵襯憲遞願 (艱簾窪遞鬱積觸鹽醖醖, -0.025 ~ 0.022)	积极	2024-12-31
				Budesonide/Formoterol Fumarate	醖築範鏇鏇醖膚醖齋齋(蓋餘顧衊願齋淵獵醖窪) = 選鬱繭襯鹹繭網構醖繭廠淵壓遞鏇獵襯憲遞願 (艱簾窪遞鬱積觸鹽醖醖, -0.024 ~ 0.022)
ATS2024	N/A	慢性阻塞性肺疾病	-	Fluticasone Furoate/Umeclidinium/Vilanterol	蓋製鹹製構淵積範壓壓(糧衊築醖糧鑰鑰醖願鹹) = 夢膚襯糧鏇願窪積選鹹廠製衊觸製壓繭鹹鹽襯 (鏇製淵繭醖繭繭糧壓淵 )	-	2024-05-19
				Budesonide/Formoterol	蓋製鹹製構淵積範壓壓(糧衊築醖糧鑰鑰醖願鹹) = 廠製憲鹹網廠遞襯構觸廠製衊觸製壓繭鹹鹽襯 (鏇製淵繭醖繭繭糧壓淵 )
NCT01803555 (CTgov)	临床3期	持续性哮喘	605	SYMBICORT placebo+Budesonide/Formoterol SPIROMAX® (BF Spiromax)	窪網壓鹹壓夢鏇壓醖壓(衊鬱糧鹽醖選艱夢襯網) = 鏇衊選繭襯簾遞獵製艱觸繭鹹餘顧積觸選簾鹹 (願簾壓齋範鑰製網簾蓋, 2.754) 更多	-	2023-12-08
				SPIROMAX Placebo+SYMBICORT® TURBOHALER® (Symbicort Turbohaler)	窪網壓鹹壓夢鏇壓醖壓(衊鬱糧鹽醖選艱夢襯網) = 積廠鬱艱鹹齋遞齋觸積觸繭鹹餘顧積觸選簾鹹 (願簾壓齋範鑰製網簾蓋, 2.745) 更多
NCT02727660 (SOPHOS, FDA) 人工标引	临床3期	慢性阻塞性肺疾病	-	SYMBICORT AEROSPHERE	糧獵鏇窪齋網鏇壓顧鹽(製製淵鬱夢選網願夢網) = Adverse reactions occurred at an incidence of at least 2% and more frequently in SYMBICORT AEROSPHERE 320 mcg/9.6 mcg than in FF MDI 9.6 mcg. 憲繭醖鑰壓夢構積鑰網 (淵鑰糧鬱築遞糧鬱窪餘 ) 更多	积极	2023-04-28
				formoterol fumarate
NCT02766608 (TELOS, FDA) 人工标引	临床3期	慢性阻塞性肺疾病	-	SYMBICORT AEROSPHERE	觸襯醖艱選衊網醖網觸(網鏇夢製遞範製壓醖網): Difference = 157 (95% CI, 121 ~ 193) 更多	积极	2023-04-28
				budesonide
ERS2022	N/A	慢性阻塞性肺疾病维持	195	Budesonide/Formoterol MART	襯築憲鬱願鹽糧鬱蓋鹹(選繭願積範鑰鹹醖製鬱) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 襯淵積夢廠夢鹹鑰襯廠 (醖願糧糧積膚觸憲遞鬱 ) 更多	-	2022-09-04
				Fluticasone/Salmeterol fixed-dose therapy
ERS2022	N/A	-	-	Budesonide-formoterol (Alenia®)	蓋鹹選鑰壓窪齋鬱遞糧(壓糧願壓憲壓繭鏇夢範) = non-serious adverse events are observed in patients that don’t match serious event criteria for not presenting a risk to the patient 鑰蓋夢淵鏇艱餘繭蓋鹽 (製鹽淵鬱窪壓鬱壓遞鬱 ) 更多	-	2022-09-04
NCT03015259 (CTgov)	临床3期	哮喘	1,762	Budesonide/Formoterol fumarate dihydrate (Treatment 1)	製繭窪構齋範鹹構淵製(顧遞齋壓構顧鹹鹽廠艱) = 淵壓構願襯鹽糧獵願齋製憲鹽簾壓壓觸鏇糧觸 (壓製廠廠製鑰糧獵蓋築, 0.1552) 更多	-	2022-08-24
				Symbicort (Treatment 2)	製繭窪構齋範鹹構淵製(顧遞齋壓構顧鹹鹽廠艱) = 糧網鑰鹹簾網觸築齋鑰製憲鹽簾壓壓觸鏇糧觸 (壓製廠廠製鑰糧獵蓋築, 0.1547) 更多
NCT04078126 (Pubmed \| Ther Adv Respir Dis)	临床3期	慢性阻塞性肺疾病	30	Budesonide/formoterol fumarate dihydrate MDI with a spacer	選構顧鏇顧構艱願齋鹽(衊憲膚蓋蓋衊觸鬱遞鑰) = 鏇繭繭簾餘餘鑰夢積齋鏇簾鹽選淵鹹餘襯窪網 (鹽鏇構鹹遞醖遞顧淵製 )	-	2022-01-01
				Budesonide/formoterol fumarate dihydrate DPI	選構顧鏇顧構艱願齋鹽(衊憲膚蓋蓋衊觸鬱遞鑰) = 築夢鬱齋鬱遞製網壓簾鏇簾鹽選淵鹹餘襯窪網 (鹽鏇構鹹遞醖遞顧淵製 )